BLFs treatment effectively reduced TNFα and IL-1β levels in both normal and AD mice, although it had no significant impact on Rab7 and Hif3α, especially in AD mice not affected by circadian rhythm disruption. The gene discussed is IL1B; the disease is Alzheimer disease.